Biotechnology company ImmunoPrecise Antibodies Ltd (NASDAQ: IPA) revealed on Wednesday that it has developed a groundbreaking class of GLP-1 therapies using its proprietary LENSai artificial intelligence platform. These AI-designed therapeutics aim to surpass existing GLP-1 treatments for type 2 diabetes and obesity by enhancing efficacy, safety, therapy longevity and patient compliance.

The therapies, optimised for stability, resistance to degradation and improved delivery methods, include potential transdermal applications as an alternative to injections. Leveraging rational genetic engineering rather than chemical modifications, IPA's approach enhances therapeutic longevity and performance while enabling efficient manufacturing and innovative administration routes.

In collaboration with Aldevron, IPA has aligned its therapies with nucleic acid-based delivery systems, integrating AI-driven optimisations to boost gene expression and minimise immune responses. These advancements position the therapies for long-term, stable production within the body, currently under preclinical evaluation.

LENSai's rapid, in silico sequence development underscores its transformative potential, identifying key molecular features and optimising drug design with unparalleled speed and precision. This method, powered by IPA's exclusive HYFT® technology, drives the evolution of biologics and offers scalable drug development solutions for the industry.

ImmunoPrecise Antibodies, known for multi-omics modeling and AI-driven solutions, continues to expand its portfolio of innovative therapeutic candidates, setting a new benchmark in drug discovery and development.